MedTrace Logo

Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis

NCT00709722 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2017-01-10

Study results available
· View outcomes & findings →

Summary

The aim of the open multi-center study is to determine an efficient and safe dose and dosing schedule of NKT-01 in induction of response in treatment of lupus nephritis.

Conditions

Interventions

DRUG

NKT-01

SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.

Sponsors & Collaborators

  • Nippon Kayaku Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hanns-Martin Lorenz, Professor · Heidelberg University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • Czechia
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00709722 on ClinicalTrials.gov